Latest News

Celleron finds international backers for oncology therapeutics

1st February 2017

All News | Financial News | Spinouts & Startups

Oxford spinout Celleron Therapeutics raises funding from South Korean consortium of investors for small molecule treatments.

Novo Nordisk to invest £115m in Oxford’s research

31st January 2017

All News | Financial News

Danish pharmaceutical firm Novo Nordisk partners Oxford University on ten-year collaboration to tackle type-2 diabetes.

OxSonics raises £9.4m in series B equity financing

9th January 2017

All News | Financial News | Spinouts & Startups

OxSonics, an Oxford University spinout established in 2013 to develop ultrasound therapeutics, has secured £9.4m in series B equity financing, bringing its total external fundraising to £14.2m.

Oxford most prolific university innovator in Europe

9th January 2017

All News | Financial News | Spinouts & Startups | Technology News

Oxford University Innovation launches 24 companies in 2016 with a combined £52.6m in early stage funding, setting a new record in spinout generation for the UK and Europe.

Oxford ‘unicorn’ Nanopore secures £100m

12th December 2016

All News | Financial News | Spinouts & Startups

Handheld DNA sequencer developer Oxford Nanopore secures £100m in funding, valuing the company at £1.25bn.

OSI’s £230m raise closes out record year for innovation at Oxford

9th December 2016

All News | Financial News

Oxford Sciences Innovation's latest fundraising rounds off year which saw Oxford University Innovation launch 22 new spinout companies.

Oxford Biodynamics completes flotation on AIM

9th December 2016

All News | Financial News | Spinouts & Startups

Biomarker spinout Oxford Biodynamics holds successful flotation on AIM.

Atopix Therapeutics acquired by Chiesi Farmaceutici

21st November 2016

All News | Financial News | Spinouts & Startups

Atopix Therapeutics Limited, a UK biotechnology company with roots back to Oxford University, has been acquired by Italian pharmaceutical firm Chiesi Farmaceutici Spa.

LAB282 – Accelerating drug discovery at Oxford to benefit patients, healthcare and society

10th November 2016

All News | Financial News | Technology News

Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research.

Oxford spinout to develop cancer therapies which reprogram tumours to die

19th October 2016

All News | Financial News | Spinouts & Startups

Oxford spinout Argonaut Therapeutics is developing cancer drugs which reprogram cancer cells to undergo the body’s natural process of cell death, shrinking tumours. The company will focus on treatments for colorectal cancer and lymphoma.

News

Ready to get in touch?